Recent Updates
Recently added Catalysts

Albumin

Phase 4

Alzheimer's Disease | Biologics | Neurology |Grifols, S.A.|Trials Updated: Jun 6, 2025

Albumin development status

Highest phase Phase 4 (NCT00968695)
Phase scored for GRFSPhase 2/3
Registered trials 10 across 8 sponsors since Aug 2008

Albumin target and mechanism

ModalityBiologics

Also known as Albumin 5%, Human Albumin 5%, Albutein 5%

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindNO_TREATMENT_CONTROLLED
Total Trials5
Total Enrollment824

FDA Designations

No designations recorded

Albumin clinical trials

Albumin · 5 trials · 3 indications

Phase 3 1Phase 2/3 1Phase 2 3
NCT03451292Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesDecompensated Cirrhosis and Ascites
COMPLETED410 Analytics
PHASE3COMPLETED
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and AscitesUnlock trial analytics

Study Endpoints

Primary Endpoints

Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event
Up to Day 361

Time to one-year transplant-free survival was calculated as earlier of \[(date of liver transplantation or date of death) - randomization date + 1\] for participants who died or had liver transplant within the analysis period of 361 days. Participants who neither died nor had liver transplant within analysis period had their time to event censored at earlier of date of last contact or cut-off date. Participants who terminated early for reasons other than death were followed up at months 3, 6, and 12 to collect information on liver transplantation and death, these events if reported by cut-off Day 361, were considered for the endpoint. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off Day 361) / (number of participants in the ITT group)\].

Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months)
Baseline and 14 months

ADAS-Cog total score as a change from baseline to 14 months The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment.

Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score (Changes From Baseline to 14 Months)
Baseline and 14 Months

ADCS-ADL total score as a change from baseline to 14 months The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).

Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score
Baseline (Week 0), Weeks 4, 12, 25, 36, and 48

The ALSFRS-R includes 12 questions to assess the self-sufficiency of participants in 3 sub-domains: bulbar function (questions 1-3), fine and gross motor function (questions 4-9), and respiratory function (question 10-12). Aspects of nourishment, personal care, personal autonomy, and communication were also evaluated. Each task was graded on a five-point scale from 0 (incapable) to 4 (normal ability), with total score range from 0 (worst) to 48 (best). A positive change from Baseline indicates improvement.

Change From Baseline in Percent Predicted Forced Vital Capacity (FVC)
Baseline (Week 0), Weeks 4, 12, 25, 36, and 48

The FVC measured the volume of air that can forcibly be exhaled through a spirometer after a full inspiration. It was expressed in a percentage of actual FVC over the expected FVC result in the general population, calculated as: Percent predicted FVC (in %) = \[(observed FVC in liters)/(predicted FVC in liters)\]\*100.

Changes From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Baseline, Weeks 4, 12, 25, 36, and 48

Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) includes 12 questions classified into 3 subdomains: bulbar function (3 questions), fine and gross motor skills (6 questions), and respiratory function (3 questions) to assess the level self sufficiency. Each task was graded according to a 5-point scale from 0 (incapable) to 4 (normal ability) with a total score from 0 (worst) to 48 (best).

Changes From Baseline in Percent Predicted Forced Vital Capacity (FVC)
Baseline, Weeks 4, 12, 25, 36, and 48
Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels.
Baseline and up to week 44

Change in levels of Aβ1-42 in CSF in the period between baseline lumbar puncture (before the start of treatment) and lumbar puncture immediately after the end of the last plasma exchange (whenever this may be). Separate assays of Aβ1-42 were performed with Innotest and The Genetics Company commercial kits.

Secondary Endpoints

Time to Liver Transplantation or Death Through 3 Months After Randomization: Percentage of Participants With an Event
Up to Day 91
Time to Liver Transplantation or Death Through 6 Months After Randomization: Percentage of Participants With an Event
Up to Day 181
Time to Death Through 3 Months After Randomization: Percentage of Participants With an Event
Up to Day 91
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SMT + Albutein 20%EXPERIMENTALParticipants received Albutein 20%, at a dose of 1.5 grams/kilograms (g/kg), based on their body weight (maximum 100 grams per participant), as an intravenous (IV) infusion on Day 1, followed by the same dose of Albutein 20% every 10±2 days along with standard medical treatment (SMT) administered as per institution standards for the management of decompensated cirrhosis up to 12 months.
SMTACTIVE_COMPARATORParticipants received SMT up to 12 months as per institution standards for the management of decompensated cirrhosis.
High Albumin + ImmunoglobulinEXPERIMENTALTherapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
Low Albumin + ImmunoglobulinEXPERIMENTALTherapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
Low AlbuminEXPERIMENTALTherapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
Control (sham) groupNO_INTERVENTIONSimulated plasma exchange procedure
Albutein 5%EXPERIMENTALPlasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
AlbuminEXPERIMENTALPlasma exchange with Albumin
ControlSHAM_COMPARATOR -

Interventions

NameTypeDescription
Albutein 20%DRUGInjectable solution
SMTOTHERParticipants received SMT according to institution standards for the management of decompensated cirrhosis.
Albumin 5%BIOLOGICALTherapeutic plasma exchange with human albumin 5%
Albumin 20%BIOLOGICALLow volume plasma exchange with human albumin 5%
ImmunoglobulinBIOLOGICALIntravenous human immunoglobulin 5%
Albutein 5%BIOLOGICALAlbutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
Plasma ExchangePROCEDUREPlasma Exchange will be performed using albutein 5% as the replacement solution.
AlbuminBIOLOGICAL27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution: * three weeks of intensive treatment with two plasma exchanges per week * twenty-one weeks of maintenance treatment with one weekly plasma exchange
ControlOTHERControl group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites66

Inclusion Criteria: * Male or female participants ≥18 years of age. * Participants with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology). * Participants who have been hospitalized for acute decompensation of liver cirrhosis with...

Countries:United StatesBelgiumBosnia and HerzegovinaBulgariaCanadaDenmarkFranceGermanyHungaryItalyPolandSerbiaSpainUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about Albumin

What is Albumin 5% used for?

Albumin 5% has been studied in clinical trials for Alzheimer's disease and amyotrophic lateral sclerosis, also known as ALS. It is a plasma-derived human albumin product developed by Grifols, S.A. under the ticker GRFS. Both programs are Phase 2 and the trials have been completed.

Who makes Albumin 5%?

Albumin 5% is made by Grifols, S.A., which trades under the ticker GRFS. Grifols is the developer associated with the clinical programs studying this human albumin product in Alzheimer's disease and amyotrophic lateral sclerosis.

What phase is Albumin 5% in?

Albumin 5% is in Phase 2 development. It is investigational and is not approved for Alzheimer's disease or amyotrophic lateral sclerosis. Two Phase 2 trials have been completed, and no trials are currently active.

What clinical trials is Albumin 5% in?

Albumin 5% has been studied in two completed Phase 2 trials. NCT01561053 evaluated albumin and immunoglobulin in Alzheimer's disease across the United States and Spain with 347 participants. NCT02479802 evaluated plasma exchange with albumin in amyotrophic lateral sclerosis in Spain with 13 participants.

Is Albumin 5% the same as Albumin (Human) 20% or Albumin 25%?

Yes. Albumin 5% is also known as Albumin, Albumin (Human) 20% United States Pharmacopeia, Albumin 20% United States Pharmacopeia, Albumin (Human) 25% United States Pharmacopeia, and Albumin 25% United States Pharmacopeia. These names refer to the same human albumin product.

How many patients were enrolled in Albumin 5% trials?

The Albumin 5% clinical program enrolled 347 participants in total. The Alzheimer's disease trial NCT01561053 accounted for 347 participants, while the amyotrophic lateral sclerosis trial NCT02479802 enrolled 13 participants. Both were randomized, double-blind Phase 2 studies.